Trials / Unknown
UnknownNCT00157976
Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 660 (planned)
- Sponsor
- Miravant Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Photrex (rostaporfin) |
Timeline
- Start date
- 2005-09-01
- First posted
- 2005-09-12
- Last updated
- 2005-12-01
Locations
4 sites across 4 countries: Bulgaria, Czechia, Poland, Romania
Source: ClinicalTrials.gov record NCT00157976. Inclusion in this directory is not an endorsement.